Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome
- 1 May 2004
- journal article
- case report
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 22 (3) , 193-196
- https://doi.org/10.1016/j.urolonc.2004.01.011
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416Journal of Clinical Oncology, 2003
- The natural history of hemangioblastomas of the central nervous system in patients with von Hippel—Lindau diseaseJournal of Neurosurgery, 2003
- Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416Ophthalmology, 2002
- Novel therapies for renal cell carcinomaExpert Opinion on Investigational Drugs, 2001
- Expression Levels of Genes that Regulate Metastasis and Angiogenesis Correlate with Advanced Pathological Stage of Renal Cell CarcinomaThe American Journal of Pathology, 2001
- von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor TherapyThe Oncologist, 2000
- Receptor tyrosine kinases as targets for inhibition of angiogenesisDrug Discovery Today, 1997
- Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease geneHuman Molecular Genetics, 1995
- von Hippel-Lindau disease: genetic, clinical, and imaging features.Radiology, 1995